-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Moyamoya disease (MMD) is a rare chronic progressive cerebrovascular disease characterized by stenosis and occlusion of the distal carotid artery, the proximal middle cerebral artery and the anterior artery, and the formation of small collateral vascular networks .
Vascular fusion of superficial temporal artery of vascular dura mater
All patients with MMD who received EDAS treatment in the Department of Neurosurgery, Fifth Medical Center of the Chinese People's Liberation Army General Hospital from January 2002 to January 2015 were selected.
From January 2002 to January 2015, 83 patients with MMD who underwent EDAS treatment in the Department of Neurosurgery of the Fifth Medical Center of the Chinese People's Liberation Army General Hospital were included in this study.
A total of 150 cerebral hemispheres received EDAS treatment.
Stroke
Baseline characteristics of the patient
Baseline characteristics of the patientEDAS is an important part of the surgical treatment of MMD.
In this study, a good Matsushima classification was found to occur significantly more frequently in patients with a younger age of onset, posterior circulation involvement, poor neurological condition, poor spontaneous collateral circulation, and RNF213 p.
The authors speculate that patients with heterozygous mutations of RNF213 have more severe cerebral ischemia, and the hypoxic brain environment mobilizes the proliferation and activation of vascular endothelial cells, thereby obtaining better collateral circulation after surgery.
Preventing these findings indicates that not only homozygous but also heterozygous p.
R4810K can be used as a specific biomarker for severe MMD, indicating the need for early interventional revascularization surgery.
WangQ ,YangR ,ZouZ WangQ Wang YangR Yang ZouZ Zou , et al bmj.
com/content/early/2021/03/29/jnnp-2020-325401" target="_blank" rel="noopener">Predictors of neoangiogenesis after indirect revascularisation in moyamoya disease: a 10-year follow-up study Journal of Neurology, Neurosurgery & Psychiatry Published Online First:30 March 2021.
Published Online First: doi:10.
1136/jnnp-2020-325401 doi: Leave a message here